An Open-Label, Multi-Center Phase II Trial of Neoadjuvant Irinotecan in Combination With Infusional 5-FU, Leucovorin (Folfiri) Plus Bevacizumab in Patients With Unresectable Hepatic-Only Metastases of Colorectal Carcinoma
Latest Information Update: 14 Sep 2010
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
- Indications Cancer metastases; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 16 Oct 2006 Status change
- 31 Aug 2006 Status change
- 08 Aug 2005 New trial record.